key: cord-0751606-qf1gqxl5 authors: Li, Jing; Liu, Bin title: The roles and potential therapeutic implications of C5a in the pathogenesis of COVID-19-associated coagulopathy date: 2020-12-13 journal: Cytokine Growth Factor Rev DOI: 10.1016/j.cytogfr.2020.12.001 sha: 0f02eafde863395f167081f23c8a208b5ba1ef60 doc_id: 751606 cord_uid: qf1gqxl5 Emerging evidence has documented that multisystem organ failure in coronavirus disease 2019 (COVID-19) patients is strongly associated with various coagulopathies. Treatments for COVID-19-associated coagulopathy are still a clinical challenge. An advancement in the knowledge of mechanisms of the excessive or inappropriate activation of the complement cascade involved in the genesis of COVID-19-associated coagulopathy might be a fundamental approach for developing novel classes of anticoagulant drugs. In this context, there is emerging evidence indicating that C5a, a component of the complement system, and its receptors (C5aRs) play a critical role in the genesis of the COVID-19-associated hypercoagulable state. Thus, this review describes the mechanisms by which C5a/C5aR signaling participates in the cascade of events involved in the pathophysiology of COVID-19-associated coagulopathy. Furthermore, it highlights the current possibilities for the development of a novel therapeutic approach for COVID-19 patients that targets C5a/C5aRs signaling. Emerging evidence has documented that multisystem organ failure from regularly released WHO reports) [2] . Clinically, patients with coronavirus disease 2019 (COVID- 19) have labored breathing, progressive hypoxemia, elevated D-dimer levels and fibrin/fibrinogen degradation products [3] . The distinctive features of COVID-19 pulmonary autopsy specimens include diffuse intravascular coagulation and large vessel thrombosis [4] , which are linked to multisystem organ failure, including acute respiratory distress syndrome (ARDS), heart failure and kidney failure. Although additional research is needed to elucidate the relationship of these findings with the clinical course of COVID-19, emerging evidence documents that multisystem organ failure in COVID-19 patients is strongly associated with various coagulopathies. The latest data suggest that the incidence of thrombotic complications is between 16% and 49% in patients with COVID-19 admitted to intensive care units [5] . However, a central question that could inform the management of COVID-19-associated coagulopathy remains under debate: are the hemostatic changes a consequence of severe inflammation, or are they a specific effect mediated by the virus [5] ? The pathogenesis of COVID-19-associated coagulopathy has not been fully elucidated. However, recent studies have indicated that thrombogenic coagulopathy in COVID-19 patients is mediated through C5a and its receptors (C5aRs) [9] . In this article, we summarize recent developments in our understanding of the role of C5a in mediating J o u r n a l P r e -p r o o f COVID-19-associated coagulopathy. The complement system plays an important role in host defense against microbial infection. However, the complement cascade can be excessively or inappropriately activated through three major pathways (namely, the classical, alternative and lectin pathways) in different courses of COVID-19 [6] . The classical pathway is activated by the C1q/r/s complex assembled on antigen-bound antibodies or in an antibody-independent manner, resulting in generation of the cofactor C4b, which accelerates enzymatic generation of C3a, C3b and the mild anaphylatoxin C4a [7] . The lectin pathway is initiated by mannose binding lectin (MBL)/MBL-associated serine proteases (MASPs) attached to carbohydrates on the surface of microorganisms. Both pathways converge to release the common C3 convertase (C4bC2b), which results in C3b/C3a production. The alternative pathway is constantly activated by spontaneous hydrolysis of the intramolecular thioester within C3, thus providing C3 convertase (C3(H2O)Bb/C3bBb), which cleaves C3 into anaphylactic and antimicrobial C3a and C3b, an opsonin that is deposited on nearby surfaces and serves to amplify activation signals. C3b also serves to generate the next generation C5 convertases. Notably, the common pathways converge on complement C5 [8] . Cleavage of C5a and C5b successively leads to the production of the C5b-9 membrane attack J o u r n a l P r e -p r o o f complex (MAC), which lyses target cells, resulting in cell death [9] . A schematic representation of the complement cascade activation pathway is shown in Figure 1 . As a potent inflammatory mediator and chemoattractant, the complement anaphylatoxin C5a contributes to endothelial barrier loss and organ injury and potentially enhances the pathogenesis of COVID-19-associated coagulopathy [10] . Coagulation disorders are emerging as an important issue in patients with COVID-19 [11] . COVID-19 is associated with thrombogenic coagulopathy with a range of presentations [12] . Preliminary reports on initial coagulopathy of COVID-19 have shown that infected patients may have elevated D-dimer (46.4%) and commonly develop thrombocytopenia (36.2%) [13] , and these rates are even higher in patients with severe COVID-19 (59.6% and 57.7%, respectively) [13] . Emerging data support that prominent elevation of D-dimer and fibrin/fibrinogen degradation product levels and abnormalities in platelet counts, prothrombin time, and partial thromboplastin time are associated with poor prognosis in patients affected by the novel coronavirus [3, 11] . Additionally, as the distinctive feature of COVID-19-associated coagulopathy, thromboses can occur in all severities of COVID-19 and range from small to large vessel clots [14] , among which recent studies have documented the presence of disseminated intravascular coagulation J o u r n a l P r e -p r o o f (DIC), microvascular thromboses, pulmonary emboli [4] , aortoiliac and mesenteric thrombi [15] , and large vessel strokes [16] . Findings from the SARS-CoV-2 pandemic indicate that the presence of coagulopathy is consistently associated with disease severity and mortality in patients with COVID-19. Coagulopathy has been reported in up to 50% of patients with severe COVID-19 manifestations [17] . Autopsy studies of patients who died of COVID-19 identified small vessel occlusion and endotheliitis in the lungs, kidneys, liver, heart, and intestine [18] . Additionally, a recent study indicated that multiple processes may contribute to COVID-19-associated microvascular and macrovascular thrombosis. These processes include cytokine storm with activation of leukocytes, endothelium and platelets, resulting in upregulation of tissue factor, activation of coagulation, thrombin generation and fibrin formation; disrupted coagulation with imbalances in plasminogen activator inhibitor-1 (PAI-1) and tissue factor pathway inhibitor; activation of protein C, which promotes fibrin generation and limits fibrinolysis; and direct viral effects resulting in cell activation [17] . These findings highlight that dysregulation of coagulation and fibrinolysis pathways contributes to COVID-19 severity, possibly through altering the hemostatic balance with subsequent coagulation-induced ischemic injury. The complete spectrum of presentations of COVID-19-associated coagulopathy has not been fully elucidated. Both D-dimer elevation and thrombocytopenia can be explained by the excessive activation of the coagulation cascade and platelets [11] . Multiple pathogenetic mediators are involved in the imbalance between procoagulant and anticoagulant homeostatic mechanisms in COVID-19, including endothelial dysfunction [19] , neutrophil activation and neutrophil extracellular trap (NET) release [20, 21] , and complement system activation [22] . Emerging data suggest that C5a activation provides rapid protection from infectious challenge and can also transition to the 'dark side', becoming a driver or exacerbator of pathology in COVID-19-associated coagulopathy [10, 23] . Human C5a C5aR2, also referred to as C5L2 or GPR77, is abundantly expressed in human tissues, such as the bone marrow, spleen and lungs [25] . It displays predominant intracellular expression in most myeloid cells and selected T cell subsets, such as neutrophils, monocytes, monocyte-derived macrophages, and NK cells [29] . Although a detailed mechanism of C5aR2 signaling and its functional consequences remains to be elucidated, recent progress has shown that C5aR2 binds C5a and desarginated C5a inflammasomes [31] . Fatal COVID-19 has been associated with a systemic inflammatory response accompanied by a coagulopathy state and organ damage, particularly microvascular thrombi in the lungs and kidneys. As the strongest inflammatory peptide in the complement cascade that induces proinflammatory cytokine release [32] , C5a and C5aRs involved in the pathogenesis of SARS-CoV-2 infection were examined in a recent study [33] . We review recent developments in the role of C5a in mediating COVID-19-associated coagulopathy through the prism of Virchow's triad. Emerging studies have shown that extensive endotheliitis in the lung, heart, kidneys, liver, and small bowel is associated with an accumulation of inflammatory cells in patients with severe COVID-19 [34] . Endothelial (ClinicalTrials.gov Identifiers: NCT04288713, NCT04346797, and NCT04355494) [34] . Normalization of the vascular wall through a C5a inhibitor could be considered a potential route of intervention in COVID-19-associated coagulopathy. The vascular endothelium is a dynamic endocrine, paracrine, and shown that thrombotic events in COVID-19-associated coagulopathy are associated with endothelial cell dysfunction [19] . Moreover, Henry et al. proposed that complement activation and direct viral invasion of the endothelium could be responsible for endothelial dysfunction [41] . Several underlying mechanisms associated with COVID-19-associated coagulopathy have not been clearly defined, but the association of endothelial dysfunction with COVID-19 and enhancement of the activated complement components C5a and C3a has been verified in severe COVID-19 patients [42] . The glycocalyx is a thick coat of proteins and carbohydrates on the outer surface of the vascular endothelium [43] . It is formed by J o u r n a l P r e -p r o o f glycoproteins and proteoglycans (PG) and has a multilayer structure that reduces endothelial contact with cellular and macromolecular blood components. The glycocalyx plays an important role in vascular homeostasis, regulating vascular permeability and cell adhesion [44] . It can also act as a mechanotransducer, enabling the detection of mechanical stress through its intracellular protein domain [44] . The link between the glycocalyx and vascular endothelial cell dysfunction in COVID-19 requires further research [45] ; however, evidence increasingly suggests that COVID-19 induces multiple injuries, including damage to the endothelial glycocalyx and endothelial dysfunction, which has been attributed to endothelial activation and dysfunction [46] . Interestingly, Bongoni et al. demonstrated that complement protein C5a plays a key role in endothelial dysfunction through damage to the vasculoprotective endothelial glycocalyx [47] . The combination of endothelial dysfunction and complement C5a may contribute to the overall procoagulative state described in COVID-19. Recent prospective studies of autopsy findings from consecutive deaths from COVID-19 found that thromboembolic events were a common cause of mortality in patients infected with COVID-19 [48] . Initial cohort studies showed that the incidence of thromboembolic [55] , increased NETs [56] and pyroptosis, and miscellaneous other mechanisms that contribute to the loss of regulatory control of proinflammatory cytokine production [57, 58] . Cellular entry of SARS-CoV-2 depends on the binding of S proteins covering the surface of the virion to the cellular angiotensin-converting enzyme 2 (ACE2) receptor [59] . After entering respiratory epithelial cells, SARS-CoV-2 provokes an immune response with inflammatory cytokine production accompanied by a weak IFN response [58] . Then, pathogenic Th1 cells and monocytes are activated, and macrophages and neutrophils infiltrate into the lung tissue, which results in a cytokine storm [60] . The involvement of the complement system in the pathogenesis of COVID-19-associated coagulopathy has been examined in several studies [61, 62] . The hyperactivation of complement C5a, which is the strongest inflammatory peptide in the complement cascade, induces the release of proinflammatory cytokines and contributes to the cytokine storm [61] . C5a and C5aRs involved in the pathogenesis of the hypercoagulable state in COVID-19 patients were examined in a recent study [33] . Recently, a combination of ruxolitinib (a JAK1/2 inhibitor) and eculizumab (an anti-C5a complement monoclonal antibody) was administered to patients with a hypercoagulable state and ARDS due to COVID-19, and very good clinical responses with a high level of safety were reported [63, 64, 65] . Figure 2 illustrates the invasion of the SARS-CoV-2 virus and the role of complement C5a in the pathogenesis of COVID-19-associated coagulopathy. Inhibitors of complement C5a have long been of interest as potential J o u r n a l P r e -p r o o f drugs for the treatment of diseases such as sepsis, ischemia-reperfusion injuries, atypical hemolytic-uremic syndrome (aHUS), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, rheumatoid arthritis, and inflammatory bowel disease [66, 67, 68] . More recently, a role of C5a inhibitors in viral infectious diseases, such as COVID-19, has been identified. In general, these small molecule C5a inhibitors can be divided into three types: anti-C5a antibodies (mAbs) [69] , C5a antagonists [66] , and chimeric C5a compounds (C-terminal-or N-terminal-modified C5a) [70] . BDB-001 is a mouse-human chimeric antibody against human C5a [33] . Experimental results demonstrated that BDB-001 can significantly alleviate N protein-induced C5a activation and lung injury in vitro and in vivo [33] . Moreover, clinical outcomes in eculizumab (an anti-C5a complement mAb)-treated COVID-19 patients showed significant improvements in respiratory symptoms and radiographic pulmonary lesions and a decrease in circulating D-dimer levels [65] . Currently, clinical trial outcomes also suggest that C5a antagonists, as anticoagulants, could be employed to minimize lung damage and prevent systemic involvement in COVID-19 patients [71] . Zilucoplan is a small compound composed of a 15-amino acid macrocyclic peptide that binds to C5 with high affinity and specificity [72] . In the field of C5 complement therapeutics for COVID-19 (shown in Table 1 ), a recent J o u r n a l P r e -p r o o f registered clinical trial (EudraCT 2020-001736-95, registered April 28, 2020) has been undertaken to evaluate the safety and efficacy of zilucoplan in COVID-19 patients [12, 73] . Collectively, the present review strongly indicates that activation of the complement anaphylatoxin C5a plays a significant role in the Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China Coronavirus disease 2019 (COVID-19) pandemic. Available from COVID-19 and its implications for thrombosis and anticoagulation Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 COVID-19 coagulopathy: an evolving story Will Complement Inhibition Be the New Target in Treating COVID-19-Related Systemic Thrombosis? Circulation Is the COVID-19 thrombotic catastrophe complement-connected? Critical role of C5a in sickle cell disease Complement Membrane Attack Complex: New Roles, Mechanisms of Action, and Therapeutic Targets Complement as a target in COVID-19? Coagulation disorders in coronavirus infected patients: COVID-19, SARSCoV-1, MERS-CoV and lessons from the past COVID-19: Complement, Coagulation, and Collateral Damage Clinical Characteristics of Coronavirus Disease 2019 in China Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia Acute aorto-iliac and mesenteric arterial thromboses as presenting features of COVID-19 Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation Endothelial cell infection and endotheliitis in COVID-19 The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit Care Neutrophil extracellular traps and thrombosis in COVID-19.medRxiv Neutrophil extracellular traps in COVID-19 Clinical promise of The Novel Receptor C5aR2 Is Required for C5a-Mediated Human Mast Cell Adhesion, Migration, and Proinflammatory Mediator Production Functional roles for C5a receptors in sepsis Bidirectional Crosstalk between C5a Receptors and the NLRP3 Inflammasome in Macrophages and Monocytes Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. medRxiv The case of complement activation in COVID-19 multiorgan impact Renal histopathological analysis of Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases COVID-19: the vasculature unleashed Vascular Endothelial Cell Biology: An Update Endotheliitis and Endothelial Dysfunction in Patients with COVID-19: Its Role in Thrombosis and Adverse Outcomes COVID-19 and Dysfunctional Endothelium: The Mexican Scenario Hyperinflammation and derangement of renin-angiotensinaldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis Hemorrhagic Problem Among the Patients With COVID-19: Clinical Summary of 41 Thai Infected Patients Equilibrium Modeling of the Mechanics and Structure of the Cancer Glycocalyx Role of albumin in the preservation of endothelial glycocalyx integrity and the microcirculation: a review. Ann Intensive Care Vascular endothelial injury exacerbates coronavirus disease 2019: The role of endothelial glycocalyx protection. Microcirculation Endothelial activation and dysfunction in metabolic syndrome, type 2 diabetes and coronavirus disease 2019 Complement -mediated Damage to the Glycocalyx Plays a Role in Renal Ischemiareperfusion Injury in Mice.Transplant Direct Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment Targeting potential drivers of COVID-19:Neutrophil extracellular traps Cytokine storm inCOVID-19:pathogenesis and overview of anti-inflammatory agents used in treatment The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 A pneumonia outbreak associated with a new coronavirus of probable bat origin Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor COVID-19 cytokine storm: The anger of inflammation Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis Anti-complement C5 therapy with eculizumab in three cases of criticalCOVID-19 Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727 Dynamics of complement activation in aHUS and how to monitor eculizumab J o u r n a l P r e -p r o o f therapy Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis Treatment of Paraquat-Induced Lung Injury With an Anti-C5a Antibody: Potential Clinical Application Agonistic and antagonistic effects of C5a-chimera bearing S19 ribosomal protein tail portion on the C5a receptor of monocytes and neutrophils, respectively Empirical Treatment and Prevention of COVID-19. Infect Chemother Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for This work was supported by grants from Tianjin Natural Science